LivaNova PLC (LIVN)
Valor JustoFundamental
64
Preço
$75.44
Capitalização de Mercado
$4.21B
Parte 1 · Quanto vale a empresa
Visão Geral
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Through its Maquet Cardiopulmonary unit, Getinge sells the heart-lung machines, oxygenators and ECMO circuits that LivaNova's Cardiopulmonary segment sells to the same hospital perfusion and cardiac-surgery departments worldwide.
Terumo's cardiovascular business supplies oxygenators, perfusion systems and disposables for open-heart surgery, overlapping directly with LivaNova's largest revenue line and competing for the same hospital tenders.
Medtronic competes on both of LivaNova's fronts — cardiopulmonary bypass equipment and disposables for cardiac surgery, and implantable neurostimulators used in drug-resistant epilepsy and difficult-to-treat neurological conditions.
NeuroPace's RNS responsive neurostimulation system targets the same drug-resistant focal epilepsy patients, and the same implanting epilepsy centres, that LivaNova's VNS Therapy depends on.
Haemonetics competes in the surgical blood-management products used in the same cardiac operating room, where LivaNova sells autotransfusion and blood-handling systems alongside its bypass equipment.
This privately held UK manufacturer sells perfusion monitoring and extracorporeal circuit systems to the same cardiac surgery units, and is named by LivaNova itself among its principal competitors.
Balanço & Liquidez
Receita
$1.47B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$189M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$173M
Capital Próprio Total
$1.20B
Passivo Total
$1.41B
Rácio de Liquidez
1.45
Cobertura de Juros
5.43
Dívida/EBITDA
1.34
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$67.01
Preço Atual
$75.44
Margem de Segurança
-12.6%
Intervalo de Valor Justo
$48.94 - $85.07
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
22.57
ROE
-20.2%
Rácio P/B
3.18
P/FCF
28.42
Margem Bruta
68.1%
ROIC
7.7%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
7.7%
WACC
9.7%
ROIC − WACC
-2.0 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (18)
- Price CAGR 5.55%
- ROIC 7.7%
- Gross Margin 68.1%
- P/FCF 28.42
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.4%
- Revenue Growth 5Y 8.2%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 10.3%
- Earnings Quality (OCF/NI) 1.32
- Share Dilution -0.0%
- Net Margin Trend 12.8% vs -16.1%
Reprovado (7)
- EPS shows upward trend
- P/B Ratio 3.18
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Piotroski F-Score 4/9
Indisponível (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Não há declarações institucionais para esta empresa.
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 52 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 55 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 54 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 50 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | - |
| Briana Gotlin | Vice President of Investor Relations | - |
| Ms. Anne M. Liddy | Chief Legal Officer | 49 |
| Deanna Wilke | Vice President of Corporate Communications | - |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | - |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 69 |
Risco de Auditoria
9
Risco do Conselho
3
Risco de Remuneração
2
Risco dos Direitos dos Acionistas
2
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-25
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-05
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-08-05
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for LIVN, sourced from Markets Gazette.
- 2/25/2026NEUTRALLivaNova (LIVN) Q4 2025 Earnings Call Transcript
The transcript of LivaNova PLC's Q4 2025 earnings conference call is now available, providing investors with a critical opportunity to delve into the company's financial performance and future outlook. While the specific content has not been disclosed, analysts and shareholders will be scrutinizing management's statements regarding revenues, profit margins, product pipeline, and guidance for the current fiscal year. This data is essential for assessing LivaNova's operational health and anticipating potential stock movements, thereby influencing both short-term and long-term investment strategies.
via Markets Gazette